Navigation Links
Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services

OMAHA, Neb., April 26 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced that Katherine A. Richardson, Ph.D. has joined the company as Technical Director for Laboratory Services.  Dr. Richardson will be responsible for managing the day-to-day operations of Transgenomic's Laboratory Services labs, and will report to Craig Tuttle, Transgenomic's president and chief executive officer.

Dr. Richardson has more than 25 years of genetic laboratory experience. She joins Transgenomic following eight years as a scientist with OSI Pharmaceuticals, where she specialized in molecular biology research and development in the area of oncology.  Previously Dr. Richardson was with Eli Lilly and Company for nine years as a senior toxicologist specializing in genetic toxicology and molecular carcinogenesis.

"Dr. Richardson has an impressive background and we are pleased to welcome her to Transgenomic," said Mr. Tuttle. "She clearly has the stature and expertise in the scientific community we are looking for as we further develop our laboratory services business as well as very strong ties to pharmaceutical research which should help us further expand our Pharmacogenomics services business.  Dr. Richardson has to her credit nearly 60 publications, abstracts and presentations at scientific conferences, and she was part of the group at Eli Lilly that identified the link between the BRCA-1 gene and hereditary breast cancer.  In particular, we look forward to tapping Dr. Richardson's extensive experience in pharmaceutical drug development and companion diagnostic testing as well as in regulatory and laboratory operating procedures."

Dr. Richardson holds an S.B. degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular cellular developmental biology from Iowa State University.  

About Transgenomic, Inc.

Transgenomic, Inc. ( is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,475 systems have been shipped to customers in more than 30 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast
3. Transgenomic, Inc. Forms Scientific Advisory Board
4. Transgenomic Appoints David Pauluzzi to Board of Directors
5. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
6. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
7. Transgenomic Opens Pharmacogenomics Laboratory in China
8. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
9. Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
10. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
11. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
Breaking Biology News(10 mins):